- Home
- INSP vs ZLAB Comparison
INSP vs ZLAB Comparison
Compare INSP & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSP
- ZLAB
- Stock Information
- Founded
- INSP 2007
- ZLAB 2013
- Country
- INSP United States
- ZLAB China
- Employees
- INSP N/A
- ZLAB N/A
- Industry
- INSP Medical/Dental Instruments
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- INSP Health Care
- ZLAB Health Care
- Exchange
- INSP Nasdaq
- ZLAB Nasdaq
- Market Cap
- INSP 3.8B
- ZLAB 3.6B
- IPO Year
- INSP 2018
- ZLAB 2017
- Fundamental
- Price
- INSP $77.31
- ZLAB $31.28
- Analyst Decision
- INSP Buy
- ZLAB Buy
- Analyst Count
- INSP 15
- ZLAB 6
- Target Price
- INSP $154.00
- ZLAB $57.22
- AVG Volume (30 Days)
- INSP 1.1M
- ZLAB 534.4K
- Earning Date
- INSP 11-03-2025
- ZLAB 11-11-2025
- Dividend Yield
- INSP N/A
- ZLAB N/A
- EPS Growth
- INSP 756.73
- ZLAB N/A
- EPS
- INSP 1.74
- ZLAB N/A
- Revenue
- INSP $861,312,000.00
- ZLAB $427,799,000.00
- Revenue This Year
- INSP $14.85
- ZLAB $41.80
- Revenue Next Year
- INSP $14.64
- ZLAB $49.93
- P/E Ratio
- INSP $43.14
- ZLAB N/A
- Revenue Growth
- INSP 22.05
- ZLAB 32.56
- 52 Week Low
- INSP $70.77
- ZLAB $23.82
- 52 Week High
- INSP $216.01
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- INSP 44.12
- ZLAB 43.80
- Support Level
- INSP $75.89
- ZLAB $29.82
- Resistance Level
- INSP $82.40
- ZLAB $33.97
- Average True Range (ATR)
- INSP 3.01
- ZLAB 1.05
- MACD
- INSP 0.97
- ZLAB -0.16
- Stochastic Oscillator
- INSP 56.19
- ZLAB 29.80
About INSP Inspire Medical Systems Inc.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.